And it’s still on the Market?
Love the commercials with the “Non-Actors”
The U.S. Food and Drug Administration (FDA) sure missed the ball on this one. Pfizer’s once touted stop smoking drug has receated yet another black eye: A study published in the Canadian Medical Association Journal found that Pfizer’s anti-smoking drug Chantix poses significant cardiovascular risks, and is linked to a 72% greater risk of hospitalisation due to a serious adverse cardiovascular event like a heart attack or arrhythmia.
Since being “released” rather quickly in 2006, Chantix has been linked to serious psychiatric events. Those events had included suicide and depression. As a result from this a black box warning was placed on the drug. Among users some people have endured alterations in hostility, behavior, depressed moods and suicidal thoughts or actions while using this stop smoking drug.